On March 18, 2021, Boston Scientific Corporation announced it received approval from the U.S. Food and Drug Administration (FDA) for the TheraSphere™ Y-90 Glass Microspheres for the treatment of patients with hepatocellular carcinoma (HCC). TheraSphere is the only radioembolization technology indicated for the treatment of unresectable HCC in the United States.
Read Boston Scientific Corporation's announcement.
Posted 3/19/2021
Understanding both the benefits to be had from offering BsAb therapy to its community and the scope of this undertaking, Vanderbilt-Ingram Cancer Center took a novel approach with its APP-led BsAb step-up dosing clinic, which won the program a 2026 ACCC Innovator Award.
